膠芽腫治療薬の世界市場

膠芽腫治療薬の世界市場は2030年までに11億米ドルに達する見込み

2024年に8億9,930万米ドルと推定される膠芽腫治療薬の世界市場は、分析期間2024-2030年にCAGR 3.4%で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗悪性腫瘍剤は、CAGR 2.8%を記録し、分析期間終了時には4億8,150万米ドルに達すると予想されます。VEGF/VEGFR阻害剤セグメントの成長率は、分析期間中CAGR 3.1%と推定されます。

米国市場は2億4,500万米ドルと推定、中国はCAGR6.2%で成長予測

米国の膠芽腫治療薬市場は、2024年に2億4,500万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.2％を引きずる形で、2030年までに2億1,700万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.6%と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の膠芽腫治療薬市場- 主要動向と促進要因まとめ

なぜ膠芽腫は複雑でありながら、がん領域で緊急に取り組むべきターゲットなのか？

多形膠芽腫（GBM）は、最も侵攻性が高く致死的な脳腫瘍の1つであり、急速な進行、治療抵抗性、患者の生存率の低さを特徴とします。膠芽腫は浸潤性が高く、遺伝的に不均一であるため、外科的切除、放射線療法、化学療法などの標準治療は部分的にしか有効ではないです。現在の第一選択療法では、放射線療法にテモゾロミドを併用することが多いが、再発はほとんど避けられないです。薬物の透過性を制限する血液脳関門（BBB）は薬理学的介入をさらに複雑にし、効果的な薬物治療の開発を特に困難にしています。

このような障害にもかかわらず、GBMは、その臨床的重篤度と根治的治療法の欠如から、腫瘍学的薬剤開発において優先順位の高い領域となっています。分子生物学およびゲノミクスの進歩により、EGFR増幅、IDH変異、MGMTメチル化、PD-L1発現など、標的となりうるいくつかの変異やバイオマーカーが同定され、現在では精密治療戦略の指針となっています。アンメット・メディカル・ニーズと希少疾病用医薬品（オーファンドラッグ）に対する規制上の優遇措置が相まって、現在の治療法の限界を克服することを目的とした新規治療アプローチの開発に取り組むバイオテクノロジー企業や製薬イノベーターの数が増加しています。

新しい治療法と薬剤クラス別は、どのようにGBM治療の選択肢を再構築しているのか？

革新の波がGBM治療薬の状況を変えつつあり、いくつかの新しい治療薬クラスが臨床開発に参入しています。異常なシグナル伝達経路（EGFR、VEGF、PI3K/ACT/mTORなど）を標的とした標的療法が人気を集めていますが、その多くは単剤療法においてさまざまな有効性を示しています。適応抵抗性を克服するために、標的阻害剤と放射線療法や免疫チェックポイント阻害剤との併用療法が研究されています。免疫療法、特に免疫チェックポイント阻害剤（PD-1/PD-L1阻害剤など）、腫瘍溶解性ウイルス、樹状細胞ワクチンなどは、免疫の乏しい腫瘍微小環境において抗腫瘍免疫を刺激する可能性が検討されています。

遺伝子治療と腫瘍治療領域（TTF）もまた、治療ポートフォリオの重要な要素となりつつあります。いくつかの市場で承認されている非侵襲的治療法であるTTFは、交互電界によって有糸分裂を破壊するもので、しばしば化学療法と併用されます。一方、CRISPRやsiRNAプラットフォームなどの遺伝子編集技術は、発がんドライバーを沈黙させ、腫瘍抑制機能を回復させるために利用されています。さらに、ナノキャリアベースのドラッグデリバリーシステムの進歩は、BBBを迂回し、細胞毒性薬剤や遺伝子修飾薬剤を腫瘍部位に直接送達することで、全身毒性を抑えながら治療効果を高めることに有望視されています。これらの新規アプローチは、困難な臨床的課題にもかかわらず、膠芽腫治療で可能なことを再定義しています。

この市場におけるイノベーションと商業戦略を形成している動向は？

いくつかのマクロおよび科学的動向は、膠芽腫治療薬市場の技術革新の軌跡と商業力学の両方に影響を及ぼしています。注目すべき動向は、分子プロファイルに基づいて患者集団を層別化し、より的を絞った潜在的に有効な治療を可能にするバイオマーカー主導型臨床試験への依存が高まっていることです。リキッドバイオプシーや次世代シーケンサーは、実用的な変異の同定や治療反応のモニタリングに頻繁に使用されるようになっています。規制機関は、特に初期段階の試験で有望な治療法に対して、技術革新と市場参入を促進するために、ファスト・トラック、ブレークスルー・セラピー、希少疾病用医薬品の指定などの迅速な経路を提供しています。

ベンチャーキャピタルや製薬企業との提携は、特に免疫療法や遺伝子編集プラットフォームを開発する企業にとって、初期段階のイノベーションに資金を供給する上で重要な役割を果たしています。産学連携が進み、より迅速なトランスレーショナルリサーチや臨床試験インフラへのアクセスが可能になりつつあります。さらに、価格設定と償還戦略は、希少がんに対する高コストの治療に対応できるように進化しており、実臨床での転帰と生存利益を実証することに焦点が当てられています。支払者は、市場参入の前提条件として、バイオマーカーに裏付けされた価値提案とコンパニオン診断薬を要求し始めており、これは医薬品開発者がより統合的な開発戦略を採用するよう影響を及ぼしています。

膠芽腫治療薬市場の成長の原動力は？

膠芽腫治療薬市場の成長は、治療法の進歩、患者の層別化、臨床パイプラインの拡大に直接結びつくいくつかの要因によって牽引されています。プレシジョン・オンコロジー（精密腫瘍学）ツールの出現により、腫瘍サブタイプに対するより効果的なターゲティングが可能となり、ニッチな患者群における奏効率の向上と生存期間の延長が実現しつつあります。CAR-T細胞療法、新抗原ワクチン、腫瘍溶解性ウイルスプラットフォームなどの免疫療法への継続的な投資は、治療抵抗性または再発性GBM症例に対する新たなフロンティアを生み出しています。さらに、テモゾロミド、放射線療法、新規薬剤を含む併用レジメンの使用拡大により、臨床転帰が改善され、新たな標準治療が確立されつつあります。

希少疾病用医薬品（オーファンドラッグ）開発に対する規制上の優遇措置や早期承認パスウェイにより、有望な治療法、特に分子シグネチャーを標的とする治療法やBBBを貫通する革新的なデリバリーシステムを採用する治療法の市場投入までの時間が短縮されつつあります。これと並行して、デジタル画像、AIベースの治療計画、バイオマーカー解析の台頭により、臨床試験デザイン、患者選択、治療モニタリングが強化されています。膠芽腫の診断の有病率の増加は、人口の高齢化と神経画像の改善も一因となっており、患者基盤をさらに拡大しています。これらの技術的、規制的、臨床的な進歩が相まって、成長が促進され、腫瘍学で最も困難な課題の一つである有効な薬物療法の開発への取り組みが活性化しています。

セグメント

薬剤クラス別（抗悪性腫瘍剤、VEGF/VEGFR阻害剤、アルキル化剤、その他の抗悪性腫瘍剤）、流通チャネル別（病院、がん研究機関、長期療養センター、診断センター、その他の流通チャネル）

調査対象企業の例（注目の41社）

• Amgen Inc.
• Ariceum Therapeutics
• Bristol-Myers Squibb
• CNS Pharmaceuticals
• Epitopoietic Research Corporation
• ImmunityBio, Inc.
• Medivir AB
• Merck & Co., Inc.
• Mustang Bio, Inc.
• Novartis AG
• Novocure Ltd.
• Pacific Marine Biotech
• Pfizer Inc.
• Roche Holding AG
• SOM Biotech
• Sun Pharmaceutical Industries Ltd.
• Telix Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• TME Pharma AG
• TransMolecular, Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Glioblastoma Treatment Drugs Market to Reach US$1.1 Billion by 2030

The global market for Glioblastoma Treatment Drugs estimated at US$899.3 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Antineoplastic, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$481.5 Million by the end of the analysis period. Growth in the VEGF / VEGFR Inhibitors segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$245.0 Million While China is Forecast to Grow at 6.2% CAGR

The Glioblastoma Treatment Drugs market in the U.S. is estimated at US$245.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$217.0 Million by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Glioblastoma Treatment Drugs Market - Key Trends & Drivers Summarized

Why Is Glioblastoma a Complex Yet Urgently Addressed Target in Oncology?

Glioblastoma multiforme (GBM) remains one of the most aggressive and lethal forms of brain cancer, characterized by rapid progression, treatment resistance, and poor patient survival rates. The highly infiltrative nature of glioblastoma and its genetic heterogeneity make standard treatments such as surgical resection, radiotherapy, and chemotherapy only partially effective. Current first-line therapy often includes temozolomide in combination with radiotherapy, yet recurrence is almost inevitable. The blood-brain barrier (BBB), which limits drug permeability, further complicates pharmacological intervention, making the development of effective drug treatments particularly challenging.

Despite these obstacles, GBM has become a high-priority area in oncology drug development due to its clinical severity and the lack of curative therapies. Advances in molecular biology and genomics have identified several targetable mutations and biomarkers-such as EGFR amplification, IDH mutations, MGMT methylation, and PD-L1 expression-that are now guiding precision treatment strategies. The unmet medical need, coupled with regulatory incentives for orphan drugs, is attracting a growing number of biotech firms and pharmaceutical innovators to develop novel therapeutic approaches aimed at overcoming the limitations of current treatments.

How Are New Modalities and Drug Classes Reshaping GBM Treatment Options?

A wave of innovation is transforming the GBM treatment drug landscape, with several new classes of therapeutics entering clinical development. Targeted therapies aimed at aberrant signaling pathways (such as EGFR, VEGF, and PI3K/AKT/mTOR) are gaining traction, although many have shown mixed efficacy in monotherapy. Combination approaches, such as pairing targeted inhibitors with radiation or immune checkpoint inhibitors, are under intense investigation to overcome adaptive resistance. Immunotherapy, particularly immune checkpoint blockade (e.g., PD-1/PD-L1 inhibitors), oncolytic viruses, and dendritic cell vaccines, is being explored for its potential to stimulate anti-tumor immunity in an otherwise immune-cold tumor microenvironment.

Gene therapy and tumor-treating fields (TTF) are also becoming critical elements of the therapeutic portfolio. TTF, a non-invasive modality approved in several markets, disrupts mitosis through alternating electric fields and is often used in conjunction with chemotherapy. Meanwhile, gene-editing technologies such as CRISPR and siRNA platforms are being harnessed to silence oncogenic drivers and restore tumor suppressor function. Moreover, advancements in nanocarrier-based drug delivery systems are showing promise in bypassing the BBB and delivering cytotoxic or gene-modifying agents directly to tumor sites, thereby increasing therapeutic efficacy while reducing systemic toxicity. These novel approaches are redefining what is possible in glioblastoma care, despite the daunting clinical challenges.

What Trends Are Shaping Innovation and Commercial Strategy in This Market?

Several macro and scientific trends are influencing both the innovation trajectory and commercial dynamics of the glioblastoma treatment drug market. A notable trend is the increasing reliance on biomarker-driven clinical trials that stratify patient populations based on molecular profiles, allowing for more targeted and potentially effective therapies. Liquid biopsy and next-generation sequencing are being used more frequently to identify actionable mutations and monitor treatment response. Regulatory bodies are offering expedited pathways such as Fast Track, Breakthrough Therapy, and Orphan Drug Designation to encourage innovation and market entry, particularly for treatments showing promise in early-phase trials.

Venture capital and pharmaceutical partnerships are playing a crucial role in financing early-stage innovation, especially for companies developing immunotherapies and gene-editing platforms. Academic-industry collaborations are increasing, leading to faster translational research and access to clinical trial infrastructure. Furthermore, pricing and reimbursement strategies are evolving to accommodate high-cost therapies for rare cancers, with a focus on demonstrating real-world outcomes and survival benefits. Payers are beginning to demand biomarker-supported value propositions and companion diagnostics as prerequisites for market access, which is influencing drug developers to adopt more integrated development strategies.

What Is Driving Growth Across the Glioblastoma Treatment Drugs Market?

The growth in the glioblastoma treatment drugs market is driven by several factors directly tied to advances in therapy modalities, patient stratification, and the expanding clinical pipeline. The emergence of precision oncology tools is enabling more effective targeting of tumor subtypes, improving response rates and extending survival in niche patient groups. Ongoing investment in immunotherapies-including CAR-T cell therapy, neoantigen vaccines, and oncolytic viral platforms-is creating new frontiers for treatment-resistant or recurrent GBM cases. Additionally, the expanding use of combination regimens involving temozolomide, radiotherapy, and novel agents is improving clinical outcomes and setting new standards of care.

Regulatory incentives for orphan drug development and accelerated approval pathways are reducing time-to-market for promising treatments, especially those targeting molecular signatures or employing innovative delivery systems to penetrate the BBB. In parallel, the rise of digital imaging, AI-based treatment planning, and biomarker analytics is enhancing clinical trial design, patient selection, and therapy monitoring. The increasing prevalence of glioblastoma diagnoses, driven in part by aging populations and improved neuroimaging, is further expanding the patient base. Collectively, these technological, regulatory, and clinical advancements are fueling growth and revitalizing efforts to develop effective drug therapies for one of the most difficult challenges in oncology.

SCOPE OF STUDY:

The report analyzes the Glioblastoma Treatment Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents, Miscellaneous Antineoplastic); Distribution Channel (Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Amgen Inc.
• Ariceum Therapeutics
• Bristol-Myers Squibb
• CNS Pharmaceuticals
• Epitopoietic Research Corporation
• ImmunityBio, Inc.
• Medivir AB
• Merck & Co., Inc.
• Mustang Bio, Inc.
• Novartis AG
• Novocure Ltd.
• Pacific Marine Biotech
• Pfizer Inc.
• Roche Holding AG
• SOM Biotech
• Sun Pharmaceutical Industries Ltd.
• Telix Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• TME Pharma AG
• TransMolecular, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Glioblastoma Treatment Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Glioblastoma Multiforme Drives Urgent Demand for Novel Therapeutic Agents
  • Limited Efficacy of Standard Therapies Strengthens the Case for Targeted and Personalized Drug Development
  • Expansion of Genomic and Molecular Profiling Capabilities Accelerates Adoption of Precision Oncology Treatments
  • Increased Investment in Immuno-Oncology Spurs Growth of Checkpoint Inhibitors and CAR-T Cell Therapies for Glioblastoma
  • High Recurrence Rates Propel Interest in Combination Therapies and Maintenance Treatment Regimens
  • FDA Fast-Track and Orphan Drug Designations Stimulate Innovation in Experimental Glioblastoma Treatments
  • Rising Focus on Blood-Brain Barrier Penetration Challenges Drives Development of Nanocarrier and Liposomal Drug Platforms
  • Advancements in RNA-Based Therapeutics and Gene Editing Technologies Expand the Pipeline of Disruptive Drug Candidates
  • Growing Application of Artificial Intelligence in Drug Discovery Shortens Development Cycles for Glioblastoma Candidates
  • Limited Success of Traditional Chemoradiation Regimens Creates Market Openings for Adaptive and Precision Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Glioblastoma Treatment Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Glioblastoma Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Antineoplastic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for VEGF / VEGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for VEGF / VEGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for VEGF / VEGFR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Miscellaneous Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Miscellaneous Antineoplastic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Miscellaneous Antineoplastic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Cancer Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Cancer Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Long Term Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Long Term Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Long Term Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: Canada 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• JAPAN
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Japan 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• CHINA
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: China 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• EUROPE
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Glioblastoma Treatment Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• FRANCE
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: France 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: France 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• GERMANY
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Germany 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Germany 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Italy 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Italy 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: UK 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: UK 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Spain 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Spain 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Russia 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Russia 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Australia 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Australia 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• INDIA
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: India 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: India 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: South Korea 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: South Korea 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Glioblastoma Treatment Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Argentina 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Argentina 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Brazil 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Brazil 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Mexico 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Mexico 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Glioblastoma Treatment Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Iran 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Iran 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Israel 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Israel 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: UAE 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: UAE 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030
• AFRICA
  • Glioblastoma Treatment Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Glioblastoma Treatment Drugs by Drug Class - Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Africa 15-Year Perspective for Glioblastoma Treatment Drugs by Drug Class - Percentage Breakdown of Value Sales for Antineoplastic, VEGF / VEGFR Inhibitors, Alkylating Agents and Miscellaneous Antineoplastic for the Years 2015, 2025 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Glioblastoma Treatment Drugs by Distribution Channel - Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Africa 15-Year Perspective for Glioblastoma Treatment Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals, Cancer Research Organizations, Long Term Care Centers, Diagnostic Centers and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION